Zai Lab Announces Acceptance Of Supplemental New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid Tumors
April 21 (Reuters) - Zai Lab Ltd 9688.HK:
ZAI LAB ANNOUNCES ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR REPOTRECTINIB FOR PATIENTS WITH NTRK-POSITIVE SOLID TUMORS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Palantir Q1 2026 Earnings Preview — Is PLTR a Buy at $144?

ORCL Stock: Why Oracle May Be the Beaten-Down Tech Giant Ready for a Comeback

Nvidia Makes First Bet on Legal AI, Invests $50 Million in Legora

POET Technologies Stock Could Still Surge in 2026, but the Bar for a Breakout Is Higher Now

Is Lululemon Stock a Buy or a Risky Bet Amidst Financial Pressure and Management Changes?

Tradingkey







